Eli Lilly Stock Surges on Demand for Weight-Loss Drugs
Related Articles
-
Eli Lilly Stock Surges as Weight Loss Drugs Continue to Fuel Growth
Eli Lilly shares jumped in early trading Tuesday as the drugmaker reported first-quarter earnings above expectations and raised full year...
-
Eli Lilly lifts sales view by $2 billion on soaring weight-loss drug demand
Sky-rocketing demand for Mounjaro and Zepbound, both chemically known as tirzepatide, has propelled the drugmaker's market value above $700 billion - surpassing both Tesla and Walmart. Lilly said its raised forecast reflects "greater clarity about the company's production expansion for the remainder of the year". In the short- to mid-term, the U.S. drugmaker expects sales growth for its weight-loss and diabetes treatments to primarily depend on how much it can produce and ship.
-
Amgen stock soars on weight loss injection progress as Novo Nordisk, Eli Lilly shares slide
Amgen's update fueled concerns about potential new competition in the weight loss drug market, sending shares of Novo Nordisk and Eli Lilly lower.